Leerink Partnrs Has Negative Outlook of Immunic Q1 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Equities researchers at Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for shares of Immunic in a report issued on Tuesday, April 1st. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings of ($0.25) per share for the quarter, down from their previous forecast of ($0.22). The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunic’s Q2 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.71) EPS, FY2025 earnings at ($0.71) EPS, FY2026 earnings at ($0.53) EPS and FY2026 earnings at ($0.53) EPS.

A number of other brokerages have also commented on IMUX. D. Boral Capital reaffirmed a “buy” rating and set a $17.00 price objective on shares of Immunic in a research report on Tuesday. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. William Blair initiated coverage on Immunic in a research note on Tuesday, March 25th. They issued an “outperform” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Immunic in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Immunic has an average rating of “Buy” and an average target price of $12.67.

Immunic Trading Down 5.2 %

Shares of Immunic stock opened at $1.00 on Friday. Immunic has a 1 year low of $0.92 and a 1 year high of $2.11. The company’s fifty day simple moving average is $1.09 and its 200-day simple moving average is $1.20. The company has a market cap of $89.70 million, a price-to-earnings ratio of -0.81 and a beta of 1.91.

Institutional Investors Weigh In On Immunic

Large investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new position in Immunic in the 3rd quarter valued at $50,000. Invesco Ltd. acquired a new stake in Immunic in the 4th quarter valued at about $37,000. Jane Street Group LLC raised its stake in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares during the last quarter. HB Wealth Management LLC acquired a new stake in shares of Immunic in the fourth quarter valued at approximately $81,000. Finally, Barclays PLC acquired a new stake in shares of Immunic in the fourth quarter valued at approximately $84,000. 51.82% of the stock is currently owned by institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.